Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

The anti-HER2 antibody Trastuzumab (Herceptin) has been proven to be effective in the treatment of HER2 overexpressing breast cancer; resistance, however invariably emerges in metastatic tumors. The expression of p95-HER2, a form of HER2 with a truncated extracellular domain that lacks the Trastuzum...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandarlapaty, Sarat, Scaltriti, Maurizio, Angelini, Pierdavide, Ye, Qing, Guzman, Marta, Hudis, Clifford A., Norton, Larry, Solit, David B., Arribas, Joaquin, Baselga, Jose, Rosen, Neal
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057066/
https://www.ncbi.nlm.nih.gov/pubmed/19855434
http://dx.doi.org/10.1038/onc.2009.337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057066/
https://www.ncbi.nlm.nih.gov/pubmed/19855434
http://dx.doi.org/10.1038/onc.2009.337

Ejemplares similares